Crunch time for FDA user fees as reau­tho­riza­tion looks to hitch a ride on short-term spend­ing bill

The lifeblood of the FDA’s drug re­views — the user fees that in­dus­try pays FDA for time­ly re­views of new and gener­ic drugs over five-year pe­ri­ods …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.